Nafamostat is primarily used as an anticoagulant in medical settings, particularly during procedures like hemodialysis to prevent blood clotting. It is also employed in the treatment of acute pancreatitis due to its ability to inhibit proteases, which can reduce inflammation and tissue damage. Additionally, Nafamostat has shown potential in managing disseminated intravascular coagulation (DIC) by stabilizing blood coagulation pathways. Recent studies have explored its antiviral properties, particularly against certain viruses, including SARS-CoV-2, where it may inhibit viral entry into host cells. Its broad-spectrum protease inhibition makes it a versatile therapeutic agent in critical care and infectious disease management.